Wellcome – Health Research Board Irish Clinical Academic Training (ICAT) programme. ICAT is an exciting new all Ireland clinician PhD programme funded by Wellcome and the Health Research Board, HSE-NDTP; HSC R&D Division; and six Universities; TCD, UCD, NUIG, QUB, RCSI and UCC. The programme is coordinated by Molecular Medicine Ireland. Integrated with postgraduate medical training, ICAT will support 4 years of academic training at the beginning of higher specialist training (HST) or equivalent, with clinical and academic mentoring until completion of PhD and CCST/CCT. ICAT now seeks to appoint the first cohort of 8 well qualified and ambitious medical graduates who aspire to become the next generation of clinical academic leaders. Web link for further details Advert poster pdf 740kb

New Company: Inflazome to tackle chronic inflammatory diseases. The intellectual property is based on the Science Foundation Ireland-funded research. Luke O’Neill and his team initially discovered that a known molecule seemed to suppress the target inflammasome. In collaboration with Professor Cooper, the team developed and subsequently patented new therapeutic inhibitor compounds based on this molecule. These compounds are now being developed by Inflazome and hopes are high that they might be useful new treatments for a range of inflammatory diseases. TCD Press Office report   read the Irish Times Tue, Sep 13, 2016 Business Section

Congratulations to TBSI PIs who secured prestigious SFI awards

Wellcome Image Awards 2016 - The winning images have arrived in TBSI. These wonderful images can been seen in the Lobby. These images were on display to celebrate the 5 year anniversary of TBSI's opening. Details here

TBSI'S Luke O’Neill, is one of five academics worldwide to join a new immunology research collaboration programme operated by the global healthcare company, GSK. The Immunology Network hosts global experts to set up research labs called ‘the Immunology Catalyst’. Details here

Congratulations to Professor Luke O’Neill who has been elected as a Fellow of the Royal Society, where scientists are elected to the Fellowship by their peers as recognised leaders who have advanced their fields through their ground breaking work. Prof O’Neill has made many contributions to improved knowledge of how the human body works including metabolism, the immune system and cell signalling. He is Professor of Biochemistry in the School of Biochemistry and Immunology in Trinity College Dublin and is a leading researcher in the school and in the Trinity Biomedical Sciences Institute (TBSI), where he was the first Academic Director.

In TBSI on 13th April, Minister English announced the recipients of the 2016 SFI-Pfizer Biotherapeutics Innovation Award programme. The collaboration between SFI and Pfizer provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases. TBSI's Padraic Fallon, one of the 2015 grant recipients, spoke at the event of the positive experiences he and his team have had during the project to date, which have been not only at the research level but also the cultural level, where his research group have adopted organisational practices used by Pfizer. Professor Fallon said that the latter has been an unexpected and welcome benefit from the collaboration.

Congratulations to Luke O'Neill who has secured a €2 million Investigator Award announced through the SFI-HRB-Wellcome Trust partnership to investigate totally new theories about how certain cells behave and cause inflammation in the hope of finding new therapies. HRB news

Congratulations to TBSI's Kingston Mills and Luke O'Neill who have been awarded €2.5million to work on biomarkers and drug targets for autoimmune and other immune-mediated diseases. Professor Mills (pictured) will lead the project. This funding has been provided by SFI and international biopharmaceutical company, AbbVie.

2015